Home  >  Products  >  VHL (von Hippel-Lindau tumor suppressor ) Blocking Peptide (the N terminal of VHL)(100ug)
VHL (von Hippel-Lindau tumor suppressor ) Blocking Peptide (the N terminal of VHL)(100ug)

VHL (von Hippel-Lindau tumor suppressor ) Blocking Peptide (the N terminal of VHL)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-VHL Antibody (ARP59367_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP59367
Size: 100ug
Weight: 19kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
Alternative names: HRCA1; RCA1; VHL1
See Full Product Listings >